Compare OPXA to:
After Hours: 0.00 N/A (N/A) 7:00pm ET
| Last Trade: | 1.93 |
|---|---|
| Trade Time: | Jan 5 |
| Change: | 0.00 (0.00%) |
| Prev Close: | 1.93 |
| Open: | N/A |
| Bid: | 1.83 x 500 |
| Ask: | 2.28 x 600 |
| 1y Target Est: | 8.00 |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 0.21 - 6.93 |
| Volume: | 0 |
| Avg Vol (3m): | 399,962 |
| Market Cap: | 24.91M |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.18 |
| Div & Yield: | N/A (N/A) |
| Thu, Dec 17 | OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online |
| Thu, Dec 17 | Opexa Therapeutics, Inc. Announces Closing of $5.1 Million Registered Direct OfferingBusiness Wire |
| Thu, Dec 10 | Opexa Therapeutics to sell $5.1 million in shares to investorsat bizjournals.com |
| Thu, Dec 10 | OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial StatEDGAR Online |
| Thu, Dec 10 | Opexa Therapeutics, Inc. Announces $5.1 Million Securities OfferingBusiness Wire |
| Tue, Dec 8 | Interim Data Lifts Geron, Stem Cell Rivals MixedIndie Research |
| Wed, Dec 2 | Weak Data Keeps Bulls At BayIndie Research |
| Wed, Dec 2 | Stem Cell Stocks Explode Higher on NIH AnnouncementIndie Research |
| Wed, Dec 2 | OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online |
| Wed, Dec 2 | Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin® Development in Multiple SclerosisBusiness Wire |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.